A recent study published in the Journal of Molecular Sciences illustrates how Exo101 modulates cells and their microenvironment, to reduce inflammation and promote homeostasis. These results support the development of Exo101 as an adjuvant therapy for inflammatory skin diseases, such as psoriasis.

Psoriasis is an inflammatory skin disease, that appears as patches of red, dry, and scaly skin. Characteristically, antimicrobial peptides S100A7 and DEFB4, as well as proinflammatory mediators IL6, IL8, CXCL10, and COX2 are all found to be upregulated in psoriasis patientsWe were able to show Exo101’s effect in modulating the production of the abovementioned markers, with a particularly strong impact on antimicrobial peptides, by using a 3D model of psoriatic skinIn vivo, Exo101 did not significantly affect overall disease burden in a model of imiquimodinduced psoriasis, but markedly reduced epidermal thicknessthat is typically seen in these patients.

Overall, this publication details the immunomodulatory effectof Exo101,  which could prove beneficial to patients suffering from inflammatory skin diseases, by modulating macrophage and Tcell responses.

Click here to read this and other publications by our team.